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variant exons that can be either completely excluded (giving 
rise to CD44s) or included in various combinations (giving rise 
to CD44 variant isoforms (CD44v)). Additional glycosylations 
increase the molecules’ heterogeneity. The expression of several 
CD44v including CD44v6 is known to correlate with advanced 
stages of colorectal cancer, breast cancer, lung cancer, thyroid 
carcinoma, hepatocellular carcinoma, gall bladder carcinoma, 
ovarian carcinoma, and endometrial cancer.[17] CD44v6 expres-
sion in CD44 negative Bsp73 AS pancreatic carcinoma cells 
conferred metastatic potential to these cells.[18] One explana-
tion for the participation of CD44v6 in the metastatic process 
of such pancreatic carcinoma cells is its involvement in Met 
and VEGFR-2 signaling. Indeed, we have shown that CD44v6 
acts as a coreceptor for the receptor tyrosine kinases Met and 
VEGFR-2,[19] both involved in tumor angiogenesis and meta-
static spread. We identified three amino acids (aa) in the v6 
sequence, which are essential for the function of CD44v6 
as a coreceptor for these receptor tyrosine kinases (RTKs).[20] 
We designed small peptides containing these three amino 
acids (termed v6-peptides), and these peptides were able 
to both bind to CD44v6 expressing cells and block the func-
tion of CD44v6 protein in Met and VEGFR-2 signaling.[19b,20] 
Experiments in mouse models for pancreatic cancer revealed 
that treatment with v6-peptides inhibits tumor growth, angio-
genesis and tumor metastasis in different in vivo models for 
pancreatic ductual adenocarcinoma.[19b,21] Furthermore treat-
ment with v6-peptides resulted in the regression of preformed 
metastases.[21]
In this paper, we aim to develop v6-peptide functionalized 
nanoparticles that can selectively bind to metastatic cancer cells 
overexpressing CD44v6. We demonstrate a facile strategy to 
synthesize the v6-peptide-NHCO-PEG-NHCO-palmitic amide 
amphiphilic polymer (v6-PEG-C16), and fabricate v6-peptide 
functionalized nanoparticles by encapsulating hydrophobic 
CdTe quantum dots (CdTe-QDs). We then demonstrate the 
ability of the v6-functionalized quantum dots to selectively bind 
to CD44v6 positive tumor cells. In addition, we investigated the 
ability of the v6-PEG to inhibit metastasis in vivo.
The first step of modification of the v6 peptide is PEGylation. 
To verify whether the modified v6-peptide maintains binding 
affinity to CD44v6 proteins, we first PEGylated v6-peptide 
and tested its efficiency in inhibiting the hepatocyte growth 
factor (HGF) signaling pathway. The synthesis of v6-peptides, 
PEGylated v6-peptides (v6-PEG) as well as the amphiphilic 
v6-peptide bearing the hydrophilic PEG moiety connected to 
a hydrophobic C16 acyl chain (v6-PEG-C16) is described in 
Scheme 1. All peptide conjugates were synthesized by solid 
phase synthesis on Wang resin, followed by purification by 
preparative HPLC. PEG with average molecular weight of 
Surface functionalized nanoparticles have great potential in 
tumor diagnosis and targeted drug delivery. Various ligands, 
such as tumor targeting small molecule compounds,[1] pep-
tides,[2] antibodies,[3] and aptamers,[4] have been immobilized on 
the surfaces of nanoparticles to achieve specific tumor targeting. 
Due to its small size and simplicity, the his-gly-asp (RGD) 
peptide is commonly used to decorate nanoparticles to achieve 
specific tumor targeting.[2a] RGD functionalized nanoparticles 
have exhibited efficient targeting in a variety of tumor models, 
i.e., pancreatic/renal orthotopic mouse tumors,[5] murine hepa-
tocarcinoma transplantable liver tumor (TLT),[6] BxPC3 pan-
creatic cancer cells,[7] U87MG glioblastoma,[8] DU145 prostate 
tumor,[9] and A549 lung adenocarcinoma.[10] Other small pep-
tides, such as CCK8,[11] CRKRLDRNC,[12] F3,[13] CGKRK,[14] and 
EPPT,[15] have been used to decorate nanoparticles to achieve 
targeted tumor delivery. However, despite intense research on 
tumor targeting nanoparticles, there are very few ligands for 
surface modification of nanoparticles that can be convention-
ally synthesized while displaying highly specific and selective 
binding to cancer cells. There is an obvious need to raise the 
number and enhance the diversity of such synthetically acces-
sible small-molecule ligands to increase both the specificity and 
selectivity of tumor targeting. In addition, ligands for selective 
targeting of metastatic cells are even less common.
CD44 proteins correspond to a family of transmembrane 
glycoproteins involved in many cellular events.[16] A variety 
of CD44 isoforms is generated by alternative splicing of ten 
This is an open access article under the terms of the Creative Commons 
Attribution License, which permits use, distribution and reproduction in 
any medium, provided the original work is properly cited.
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2000 g mol−1 was used in the case of the v6-PEG synthesis. 
To synthesize v6-PEG-C16, PEG 3000 g mol−1 was attached 
to the N-terminus of the v6-peptide followed by Fmoc depro-
tection and acylation with palmitic acid. V6-peptide, v6-PEG, 
and v6-PEG-C16 were purified using HPLC as previously 
described.[22] The identity of the peptides was confirmed using 
LC-MS and the purity of the peptides and peptide-conjugates 
were found to be over 90% according to HPLC. The molecular 
weight was validated by matrix-assisted laser desorption/ioni-
zation (MALDI)-MS (Figure 1 A,B). Figure 1A shows the mass 
spectra of v6-PEG based on PEG 2000 g mol−1 and Figure 1B of 
v6-PEG-C16 based on the PEG 3000 g mol−1.
QD-PEG-v6 PEGylated quantum dot nanoparticles were suc-
cessfully synthesized by coincubating C16-PEG and C16-PEG-v6 
along with QDs in chloroform, followed by evaporation of the 
organic solution and taking up the residue in phosphate buffer. 
Three different types of v6-peptide functionalized quantum dot 
nanoparticles with varying v6-peptide concentrations were pre-
pared: PEG-QDs (0% of v6), 10% v6-PEG-QD (10% of v6), and 
30% v6-PEG-QDs (30% of v6) (see the Experimental Section).
Since QDs are stabilized with surface tetradecyl groups, we 
employed a self-assembly method to encapsulate these water-
insoluble QDs in lipid nanoparticles produced from mixtures 
of amphiphilic PEG-C16 and v6-PEG-C16.[23] All produced 
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Scheme 1. Schematic representation of the solid phase synthesis of v6-PEG and v6-PEG-C16 (top) as well as nanoparticle preparation and application 
for targeting CD44v6+ cells (bottom). i) Peptide synthesis was conducted on Wang resin using standard Fmoc solid phase peptide synthesis to synthe-
size NEWQG, ii) Fmoc-NH-PEG3000-COOH was conjugated to the free N-terminus of the immobilized peptide; iii) After Fmoc-deprotection, palmitic 
acid was conjugated to the amino terminus of the PEG using HCTU; iv) v6-PEG-C16 was cleaved from the resin using a mixture of TFA:H2O:TIS; 
v) MeO-PEG2000-COOH was conjugated to v6-peptide by amide coupling; vi) PEG-v6 was cleaved from the resin using a mixture of TFA:H2O:TIS; 
vii) preparation of v6-PEG-QDs and their selective binding to CD44v6+ cells. Nanoparticles were prepared by self-assembling of hydrophobic quantum 
dots with amphiphilic v6-PEG-C16 using the lipid film method.
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nanoparticles were characterized using dynamic light scat-
tering (DLS) (Figure 2). The average hydrodynamic diameter 
of PEG-QDs, 10% v6-PEG-QDs, and 30% v6-PEG-QDs were 
found to be 79, 106, and 132 nm, respectively (Table 1). Since 
a single QD measures 5 nm, the DLS results indicated that 
about 10–20 QDs were encapsulated in a single PEG-QD or 
v6-PEG-QD. Incorporating v6-peptide in PEG-QDs resulted 
in the particles’ reduction of zeta-potential from −14.7 mV in 
case of PEG-QDs to −30.6 and −31.7 mV in the case of 10% and 
30% v6-PEG-QDs, respectively. The decrease in zeta potential 
was most probably caused by the negatively charged carboxylic 
groups present at C-terminus (glycine) and glutamic acid side 
chains in the v6-peptide.
V6-peptides can efficiently block HGF-induced hepatocyte 
growth factor receptor (or Met) activation and downstream 
signaling.[20] Furthermore, v6-peptide treatment of HT29 colon 
carcinoma cells has been shown to strongly inhibit their HGF/
Met-stimulated cell detachment and scattering. Peptide PEGyla-
tion might inhibit the peptides’ binding to CD44v6 receptors, 
thereby resulting in a loss of biological activity. To test this 
hypothesis, we investigated whether the peptides were still able 
to block HGF-induced Met and extracellular signal-regulated 
kinase (Erk) activation after attaching a 2000 Da PEG. We 
treated the rat pancreatic carcinoma cell line BSp73ASs6 that 
highly expresses CD44v6 with v6-PEG and tested whether this 
treatment impacted HGF-induced activation of the RTK Met 
and its downstream target, Erk. We used v6-peptides (A = syn-
thesized by ourselves, B = synthesized by Bachem (Bubendorf, 
Switzerland)) as a positive control. We used nonPEGylated or 
PEGylated negative control peptides (v6 control and v6-PEG 
control) where the middle three essential amino acids were 
replaced by alanine. As shown in Figure 3, upon treating the 
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Figure 1. MALDI-MS spectra of v6-PEG based on PEG 2000 g mol−1 A) and v6-PEG-C16 based on the PEG 3000 g mol−1 B).
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Figure 2. Size distribution of QD nanoparticles based on DLS with different density in v6-peptide groups: PEG-QDs (79 nm), 10% v6-PEG-QDs (106 nm), 
and 30% v6-PEG-QDs (132 nm).
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ASs6 cells with v6-PEG, HGF failed completely to induce 
Met-phosphorylation and activate Erk signaling, whereas the 
v6-PEG control displayed no effect (Figure 3A). Furthermore, 
HGF-induced scattering of HT29 cells was strongly inhibited 
by pretreatment with v6-PEG, but not with v6-PEG control 
(Figure 3B). We then tested the v6-PEG effect in vivo in the 
L3.6pl orthotopic xenograft model for pancreatic cancer.[24] 
Treatment with the v6-PEG resulted in the primary tumor’s 
growth inhibition, similar to the v6-peptide (Figure 4A). More-
over, we detected no liver metastases in mice treated with 
v6-PEG or with v6-peptide (Figure 4B).
Many reports have demonstrated that PEGylated proteins 
lose their biological activity due to the steric interference of 
PEG at the receptor–ligand interaction site.[25] However, both 
www.advancedscience.com
Adv. Sci. 2017, 4, 1600202
www.advancedsciencenews.com
Table 1. Particle size and zeta potential of PEG-QD, 10% v6-PEG-QD, 
and 30% v6-PEG-QD measured by DLS.
Mean particle size [nm] Mean zeta potential [mV]
PEG-QD 79 ± 16 −14 ± 5
10% v6-PEG-QD 106 ± 22 −31 ± 5
30% v6-PEG-QD 132 ± 34 −32 ± 5
Figure 3. v6-PEG efficiently blocks cell scattering and HGF/Met signaling. A) ASs6 cells treated for 30 min with 150 × 10−9 m of v6-peptide (A = synthe-
sized by ourselves, B = synthesized by Bachem, Bubendorf, Switzerland), v6-PEG, v6 control, or v6-PEG control were induced with HGF (10 ng mL−1) 
for 5 min. Subsequently, Met and Erk phosphorylation were determined by western-blot analysis. p-Met and p-Erk levels were normalized to total Met 
and Erk levels, respectively. Quantification of the fold induction of activation is shown in the diagram. B) HT29 cells grown in the absence (control) or 
presence of HGF with or without v6-peptide, v6-PEG, v6 control, or v6-PEG control were visualized by phase contrast microscopy. Magnification, 40×. 
The table reflects the scattering ability of HT29 cells in the absence or presence of the respective peptides.
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the v6-peptide and v6-PEG exhibited efficient blocking in in 
vitro assays and in the animal model, indicating that PEGyla-
tion did not affect the v6-peptides’ functionality. As PEGylation 
is known to protect peptides from enzymatic degradation and 
to increase the half-life of peptides in vivo,[25c] further investiga-
tions are necessary to evaluate whether this is also the case with 
v6-peptides.
Since PEGylation did not impact the biological activities of 
the v6-peptides, we further tested v6-PEG-QDs for their ability 
to specifically bind to and stain CD44v6 expressing cells. Fur-
thermore, we analyzed whether the density of v6-peptides on 
nanoparticles would influence the binding ability. We incu-
bated CD44v6 expressing ASs6 cells (Figure S3, supporting 
information) or CD44v6 negative AS10 cells with PEG alone 
or v6-peptide decorated QD nanoparticles, followed by confocal 
fluorescence microscopy (Figure 5A). We quantified the per-
centage of QD-stained cells (n = 5, Figure 5A). The PEG-QDs 
alone did not stain any of the cells (whether CD44v6-negative 
AS10 or CD44v6-positive ASs6 cells (Figure 5A, panel 1; 
Figure 4B)). This result rules out the unspecific binding of QD 
nanoparticles to cells caused by the PEG layer. The 10% v6-PEG-
QDs were found to bind to both AS10 and ASs6 cells (less than 
10% cells), indicating that nanoparticles possessing low surface 
density of v6-peptides interacted unspecifically with both AS10 
and ASs6 cells (Figure 5A, panel 2; Figure 5B). However, 30% 
v6-PEG-QDs were found to bind to 90% ASs6 cells, whereas 
only 15% of the AS10 cells were stained (Figure 4A, panel 3; 
Figure 4B). This result demonstrates that v6-peptides’ greater 
surface density significantly increases the specific binding of 
the cargo to CD44v6-positive ASs6 pancreatic cancer cells.
To confirm the specific binding of v6-peptide-decorated nan-
oparticles to CD44v6-positive cells, we transfected AS10 cells 
with mCherry expression vectors and ASs6 cells with CFP (cyan 
fluorescent protein) expression vectors, and cocultured these 
two cells together in one plate. We treated these cocultured 
cells with 30% v6-PEG-QDs and visualized the staining via con-
focal fluorescence microscopy. The result showed that the 30% 
v6-PEG-QDs only bound to CD44v6-positive ASs6 cells (CFP 
labeled, Figure 4A, panel 4, cyan cells), while CD44v6-negative 
AS10 cells remained virtually unstained (mCherry labeled, 
Figure 4A, panel 4, red cell). This result further confirms the 
binding specificity of the 30% v6-PEG-QDs toward the CD44v6-
expressing pancreatic cancer cells ASs6.
In addition to confocal fluorescence microscopy, we ana-
lyzed the cell binding activity of different v6-peptide densities 
of v6-PEG-QDs by fluorescence activated cell sorting anal-
ysis (FACS analysis). AS10 and ASs6 cells were treated with 
phosphate-buffered saline (PBS), PEG-QDs, 10% v6-PEG-
QDs, or 30% v6-PEG-QDs prior to the FACS analysis. Con-
curring with the fluorescence microscopic results, PEG-QDs 
and 10% v6-PEG-QDs revealed no specific binding either to 
AS10 or ASs6 cells, as there was no shift in the FACS dia-
gram compared to the nontreated PBS control (Figure 4C, 
green and yellow lines). On the other hand, 30% v6-PEG-QDs 
treated ASs6 cells displayed a clear shift in the FACS dia-
gram, indicating specific binding of the high-density v6-pep-
tide-decorated QDs to the CD44v6-expressing cancer cells 
(Figure 4C, red line). In contrast to this, we observed just a 
minor shift in the AS10 cells treated with the 30% v6-PEG-QDs 
(Figure 4C, red line). This confirms that the binding of 30% 
v6-PEG-QDs to cells is dependent on the CD44v6 expression 
level. These results confirm that v6-peptide coupled to nano-
carriers can be used to distinguish between cancer CD44v6+ 
and CD44v6− cells. Furthermore, we used v6-PEG-QDs to 
stain CD44v6 directly on tumor tissue. For this purpose, we 
isolated primary tumors derived from a syngeneic rat model 
of pancreatic cancer.[21] In this model CD44v6 positive ASs6 
cells were subcutaneously injected in the flank of the animals. 
After four weeks the tumors were isolated and tumor sections 
were stained either with PEG-QDs (control), v6-PEG-QDs 
or the ratCD44v6 specific antibody 1.1 ASML (Figure 5).[18a] 
Our results demonstrate that the v6-PEG-QDs stain CD44v6-
positive tumor tissues as also observed with a CD44v6 specific 
antibody (Figure S1, Supporting Information). No staining was 
seen with PEG-QDs that were used as a control, demonstrating 
that the binding of the QDs to the tumor tissue is mediated by 
the coupled v6-peptide.
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Figure 4. A) L3.6pl were injected orthotopically into the pancreas of 
male nude mice. One week later animals were injected i.p. with the 
v6-peptide, the v6-PEG, or the v6 control (20 μg). Injection was repeated 
three times per week. Animals were killed 3 weeks after the treatment. The 
quantification represents the average tumor volume of animals treated 
either with the v6-peptide, the v6-PEG or the v6 control at the end of the 
experiment. B) Top: Bars represent the average number of metastases. 
Bottom: Macroscopic liver metastases. *** p < 0.001, n.d.: not detected, 
group size n = 3.
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Hence, v6-PEG-QDs might eventually be used as a powerful 
noninvasive theranostic tool both to treat and visualize pri-
mary tumors, metastases and metastatic pancreatic cancer cells 
expressing CD44v6. Further, analysis of the binding capability 
to CD44v6 expressing cells of other tumor types, e.g., colo-
rectal cancer or glioblastoma should be done to reveal whether 
v6-PEG-QDs can be used more generally to detect specific 
(more aggressive or metastatic) subpopulations of cancer cells 
in other cancers as well.
In addition to the imaging advantages, v6-peptide coupled 
quantum dots can serve as a platform for a combined anti-
cancer therapy. By blocking the coreceptor function of CD44v6 
for c-Met and VEGF-R, it is possible to inhibit protumorigenic 
events such as angiogenesis, tumor cell migration, and metas-
tasis; while by coupling conventional anticancer drugs such as 
gemcitabine or fluororacil to the nanocarriers, the synergistic 
anticancer effect can be achieved. Remarkably, v6-peptide cou-
pled quantum dots have a cytotoxic effect specific to CD44v6 
expressing pancreatic cancer cells (ASs6). We performed cell 
viability tests on AS10 and ASs6 cells treated with PEG-QDs 
and v6-PEG-QDs for 48 h. At 50 μg mL−1 only 50% of CD44v6 
expressing ASs6 cells were viable whereas PEG-QDs treated 
ASs6 cells were not affected at this concentrations (Figure S2, 
Supporting Information). Furthermore, no cytotoxic effect of 
PEG-QDs or v6-PEG-QDs was seen on CD44v6 negative AS10 
cells (Figure S2, Supporting Information). These results sug-
gest that the cytotoxic effect of the v6-PEG-QDs to ASs6 cells 
is dependent on the binding of the nanoparticles to CD44v6 
expressing cells and might be mediated by a cellular uptake of 
the quantum dots.
Thus, v6-peptide coupled quantum dots could be used to 
deliver cytotoxic drugs specifically to CD44v6-expressing cancer 
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Figure 5. v6-PEG-QDs bind specifically to CD44v6 expressing tumor cells A) Panels 1–3: AS10 or ASs6 cells incubated with 100 μg mL−1 PEG-QDs 
(control), 10% v6-PEG-QDs, or 30% v6-PEG-QDs were costained with DAPI and visualized by fluorescence microscopy. Panel 4: AS10 cells transfected 
with mCherry (red) and ASs6 cells transfected with CFP (cyan) were cocultured and stained with 30% v6-PEG-QDs. Magnification, 40×. B) Percentages 
of quantum dot stained cells was quantified. C) AS10 or ASs6 cells were incubated with PBS or 100 μg mL−1 PEG-QDs, 10% v6-PEG-QDs, or 30% 
v6-PEG-QDs for 10 min and analyzed by FACS measurement.
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cells without harming normal dividing cells, which would make 
conventional anticancer drugs more efficient and reduce their 
side effects. As CD44v6 is furthermore expressed in the cancer 
stem cells of several common cancers (e.g., colorectal cancer)[26] 
and those associated with high mortality (e.g., pancreatic 
cancer[27] and glioblastoma[28]) v6-peptide coupled quantum 
dots might provide a platform for combined cancer treatments 
targeting cancer stem cells within a variety of lethal cancers.
CD44v6 expression often correlates with advanced stages of 
cancer and goes hand in hand with poor prognosis in various 
cancer types. Many malignant cancer cells, including cancer 
stem cells, overexpress CD44v6 on their surface, suggesting 
CD44v6 as a marker for several types of cancer. In this paper, 
we demonstrate that the functionalization of nanoparticles with 
a small 5-amino acid peptide (Asn-Glu-Trp-Gln-Gly), v6-peptide, 
endows nanoparticles with the ability to specifically bind cancer 
cells overexpressing CD44v6 receptor. The v6-peptide was syn-
thesized by solid phase synthesis and covalently linked to a 
hydrophobic C16 chain via a PEG linker to form the v6-PEG-
C16 amphiphilic conjugate. Hydrophobic quantum dots were 
incorporated into v6-PEG-C16 lipid nanoparticles produced by 
the lipid film method. The addition of PEG-C16 amphiphiles 
into this system enabled us to fine-tune the density of surface 
v6-peptides and reduce nonspecific binding of the particles to 
cells. Our results support the hypothesis that the multivalency 
or higher density of surface v6-peptides is an important param-
eter for specific tumor targeting and essential to increasing 
binding specificity. In a separate experiment, we showed that 
apart from specific binding to CD44v6-overexpressing cancer 
cells, the in vivo application of PEGylated v6-peptide completely 
blocked metastasis formation and reduced the original tumor 
volume in a mice animal model. Such an antimetastatic effect 
is a result of the selective binding of v6-peptide to CD44v6-
expressing tumor cells. To our knowledge, there is no other 
simple small molecule system possessing both a specific tar-
geting ability as well as efficient anticancer and antimetastatic 
activities. Such dual functionality combined with the modular 
synthesis and facile preparation of nanoparticles decorated with 
the v6-peptide makes this system highly potent for improving 
the existing and for developing novel multifunctional nanocar-
riers for therapeutic and/or diagnostic anticancer applications.
Experimental Section
Materials: Human adenocarcinoma cell line HT29, a gift of A. 
Zweibaum (Institut National de la Sante et de la Récherche Medicale, 
France) was grown in Dulbecco’s modified eagle’s medium (DMEM) 
(Invitrogen, Karlsruhe, Germany) supplemented with 10% fetal calf serum 
(FCS) (PAA, Cölbe, Germany). Rat pancreatic carcinoma cells BSp73AS10 
(AS10) and its transfectant BSp73ASs6 (ASs6) were grown in Roswell 
Park Memorial Institute (RPMI) (Invitrogen) plus 10% FCS. Hydrophobic 
CdTe quantum dots were ordered from PlasmaChem GmbH (Germany, 
catalogue number PL-QDN-550) functionalized with tetradecylamine 
(emission at 550 ± 5 nm, particles molar weight is 32 000 Da, size 
2.6 nm). Palmitic acid (99%) and poly(ethylene glycol) methyl ether 
(MW 2000 g mol−1) were obtained from Sigma-Aldrich (Germany). All 
amino acids were purchased either from Novabiochem (Schwalbach, 
Germany) or Iris Biotech GmbH (Marktredwitz, Germany). The α-methoxy-
omega-carboxylic acid poly(ethylene glycol) (MeO-PEG-COOH, MW 
750 Da and 2000 Da), α-(9-fluorenylmethyloxycarbonyl)amino-omega-
carboxy poly(ethylene glycol) (Fmoc-NH-PEG-COOH, MW 3000 Da), 
2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronoium hexafluorphosphate 
(HBTU), 2-(6-chloro-1H-benzotriazol-1-yl)- 1,1,3,3-tetramethyluronoium 
hexafluorphosphate (HCTU), 1-hydroxybenzotriazole (HOBt), trifluoro-
acetic acid (TFA), triisopropylsilane (TIS), N-methyl-2-pyrrolidone (NMP), 
and N,N-diisopropylethylamine (DIEA) were purchased from Iris Biotech 
GmbH (Marktredwitz, Germany). Peptide were synthesized by following 
Fmoc-based solid phase peptide synthesis[22] and characterized using 
analytical HPLC (Agilent, Germany) coupled to electron spray mass 
spectrometer (Bruker Daltoniks, Bremen Germany).
Instrumentation: Dynamic light scattering was performed on a Malvern 
Zetasizer Nano ZS (Malvern, Germany). CdTe quantum dots nanoparticles 
were diluted with MilliQ water to a concentration of 0.1 mg mL−1. 750 μL 
nanoparticle solution was added in a cuvette, and particle size (hydrodynamic 
diameter) and surface charge (zeta potential) were measured.
Quantum dot nanoparticles were characterized by scanning electron 
microscopy (SEM) using the LEO 1530 Gemini scanning electron 
microscope (Zeiss, Germany, Institute of Nanotechnology, KIT). Samples 
for SEM were prepared by resuspending the particles in MilliQ water at 
a concentration of 0.1 mg mL−1. One drop of the resulting dispersion 
was placed onto a silicon wafer and dried in air. The particles were then 
sputter coated with gold for 20 s using a Cressington 108 auto sputter 
coater (Watford, UK) before measuring SEM.
Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) 
mass spectrometry was performed on a 4800 MALDI-TOF/TOF mass 
spectrometer (Applied Biosystems, Framingham, MA). Peak lists were 
generated using Data Explorer Software 4.0 (Applied Biosystems). 
2,5-Dihydroxybenzoic acid (10 mg in 1 mL tetrahydrofuran containing 
0.1% trifluoroacetic acid) was used as a matrix for PEGylated peptides 
and v6-PEG-C16. 10 μL PEGylated peptides and peptide-PEG-C16 
(1 mg in 1 mL MilliQ) were mixed with 10 μL matrix, and 1 μL mixed 
solution was spotted on a stainless steel MALDI plate.
Peptide synthesis was performed on an automated peptide 
synthesizer (model syroII from Multisyntech, Witten, Germany) and 
the peptides were purified by a preparative HPLC-system (Jasco, Tokyo, 
Japan). Crude and purified products were characterized by a LC-MS 
(μTOF LC-MS from Bruker Daltonics-Bremen, Germany). Preparative 
HPLC was performed on a reversed phase C18 column (vydac, 10 mm × 
240 mm) at 35 °C using a flow rate of 7 mL min−1 fitted with a diode 
array detector. Peptides and polymer-peptide conjugates were separated 
using acetonitrile/water gradients supplemented with 0.1% of TFA.
Peptide Synthesis and Polymer Conjugation: Peptide synthesis, 
PEGylation, and palmitic acid conjugation were performed using 
standard Fmoc solid phase peptide synthesis protocol on wang resin.[22] 
Fmoc deprotection was performed with 20% (vol) piperidine in NMP. 
Coupling was performed using a mixture of Fmoc-amino acid (or MeO-
PEG-COOH, Fmoc-NH-PEG-COOH, palmitic acid): HOBt:HBTU:DIEA 
(4:4:3.9:8 mol/mol) in dimethylformamide (DMF). Peptides were cleaved 
from the solid support using a mixture of TFA:H2O:TIS (93.5:2.5:4 v/v). 
The cleavage cocktail was removed under a gentle stream of N2, followed 
by precipitation of the crude peptide using diethyl ether.
Synthesis of PEG-C16: 500 mg palmitic acid was dissolved in 
30 mL of CH2Cl2 and treated with 312 μL N,N′-diisopropylcarbodiimide, 
250 mg 4-dimethylaminopyridine, and MeO-PEG-OH (4 g, average 
MW 2000 g mol−1) by stirring under nitrogen gas for 16 h at room 
temperature. The reaction solution was diluted with 100 mL cold diethyl 
ether and then cooled on ice. The white precipitate was filtered off and 
washed with sodium hydroxide solution (pH 9) to obtain PEG-C16.
Preparation of Nanoparticles: V6-peptide functionalized quantum dot 
nanoparticles were prepared as follows: (a) PEG-QDs were prepared 
by mixing 300 μL PEG2000-palmitic ester (PEG-C16, 4 mg mL−1 in 
chloroform) and 30 μL QDs (10 mg mL−1 in chloroform) in 4 mL vials. 
After vortexing for 20 s, the mixed solution was kept in an open vial 
overnight to slowly evaporate chloroform. 300 μL PBS buffer (pH 7.4) 
were added to the 4 mL vial, and vortexed for 30 s to form PEGylated 
quantum dot nanoparticles (PEG-QDs). (b) 10% v6-PEG-QDs were 
prepared by mixing 270 μL PEG-C16 (4 mg mL−1 in chloroform), 120 μL 
v6-PEG-C16 (0.5 mg mL−1 in chloroform), and 30 μL QD (10 mg mL−1 in 
chloroform) in 4 mL vials. After vortexing for 20 s, the mixed solution was 
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evaporated overnight. 300 μL PBS buffer (pH 7.4) were added to the vial, 
and vortexed for 30 s to form v6-peptide conjugated (10%) PEGylated 
quantum dot nanoparticles (v6-PEG-QDs). (c) 30% v6-PEG-QDs were 
prepared by mixing 210 μL PEG-V16 (4 mg mL−1 in chloroform), 360 μL 
v6-PEG-C16 (0.5 mg mL−1 in chloroform), and 30 μL QD (10 mg mL−1 in 
chloroform) in 4 mL vials. After vortexing for 20 s, the mixed solution was 
left open overnight to evaporate chloroform. 300 μL PBS buffer (pH 7.4) 
was added to the vial and vortexed for 30 s to form nanoparticles. 
Since a single QD measures 5 nm, the DLS results indicated that about 
10–20 QDs were encapsulated in a single PEG-QD or v6-PEG-QD.
Western Blotting and Activation of Met and Erk: ASs6 cells, serum 
starved for 24 h, were induced with HGF (10 ng mL−1) at 37 °C for 5 min. 
Where indicated, the cells were treated with PEGylated or nonPEGylated 
peptides (150 × 10−9 m) before induction at 37 °C for 10 min. Cells were 
washed with PBS and lysed in boiling sodium dodecyl sulfate (SDS) 
buffer containing 100 × 10−3 m dithiothreitol (DTT). Subsequently, 
lysates were subjected to western blot analysis using antibodies against 
phosporylated Mek and Erk (Cell signaling). The Mek and Erk loading 
controls were performed on the same blot, stripped (62.5 × 10−3 m 
Tris pH 6.8, 2% SDS, 0,8% DTT) and probed with the Mek and Erk 
antibodies. Blots were stained using the enhanced chemiluminescence 
system (Thermo Scientific, Dreieich, Germany).
Scattering Assay: Scattering of HT29 cells was determined in 24-well 
plates. First, 4 × 105 cells were seeded at 37 °C; the cells were either 
left untreated or 48 h later treated with HGF (50 ng mL−1) for 24 h or 
with PEGylated or nonPEGylated peptides (100 ng mL−1) prior to HGF 
induction for 30 min.
Confocal Fluorescence Microscopy: 1 × 104 AS10 and ASs6 cells per 
well were seeded on 20 mm glass coverslips (Menzel, Braunschweig, 
Germany) and incubated for 24 h at 37 °C. The cells were washed 
with ice-cold PBS, fixed with methanol for 15 min at −20 °C, and again 
washed three times with PBS. Afterward, cells were incubated with the 
indicated modified quantum dots for 1 h at room temperature in the 
dark. Subsequently, cells were stained with 4,6-diamidino-2-phenylindole 
dihydrochloride (DAPI) in PBS for 30 min at room temperature, washed 
three times with PBS, and mounted with fluorescence mounting medium 
(Dako, Glostrup, Denmark). Fluorescence images were taken with a 
Leica SPE laser scanning confocal microscope with a 63× objective.
Fluorescence Activated Cell Sorting: ASs6 and AS10 cells cultured in 
10 cm petri dishes were harvested at 80% confluency, with 5 × 10−3 m EDTA/
PBS. Cells were washed three times with 3% FCS in PBS. Afterward, 
cells were incubated with 100 ng mL−1 quantum dots in 3% FCS/PBS 
for 10 min. Then, cells were washed three times with 3% FCS in PBS, 
resuspended in PBS without FCS, and subjected to FACS measurement.
Cell Viability Assay: ASs6 or AS10 cells grown in a 96-well tissue culture 
plate (0,5 × 104/well) were incubated with the indicated concentrations 
of PEG- and v6-PEG-QDs for 48 h. For measuring cell viabilty cells were 
incubated with 10 μL well−1 Cell Proliferation Reagent WST-1 for 2 h and 
mixed for 1 min on a shaker. The absorption at 420 nm was determined 
with an ELISA reader EXL 808 (Biotek). Culture medium and WST-1 
reagent in empty wells were used as blank controls.
Animals: Male athymic nude mice (NCI-nu) were purchased from 
Harlan (Roßdorf, Germany). BDX rats were bred in house. Animals 
were housed and maintained under specific pathogen-free conditions in 
facilities approved by the Regierungspräsidium Karlsruhe. All animals were 
handled according to German regulations for animal experimentation. 
Experiments were authorized by the Regierungspräsidium (35-9185.817G-
192/10 and 35-9185.817G-106/09).
Orthotopic Implantation of Tumor Cells: L3.6pl cells (passage 28) 
were suspended in Hank’s balanced salt solution (Invitrogen) after 
trypsinization. The cells were injected into the pancreas of NCI-nu as 
previously described.[24] Mice were injected i.p. 7 d after tumor cell 
implantation with the v6-peptide, the v6-PEG or the control peptide 
(20 μg) where the three central amino acids were substituted with alanines 
(NAAAG). The injection was repeated three times per week for 21 d.
Immunofluorescence Stainings of Tumor Tissue: The syngeneic rat 
pancreatic cancer model is described previously.[21] Briefly, 1 × 106 
BSp73ASs6 cells were injected subcutaneously into the right posterior 
flank of BDX rats. Tumors developed for 4 weeks. At the end of the 
experiment, primary tumors were isolated. The tissues were snapfrozen 
in liquid nitrogen and cut into 4–6 μm thick sections that were mounted 
on gelatin-coated glass slides. The sections were fixed in acetone 1:1 for 
10–15 min at 4 °C. The sections were washed in PBS and blocked at room 
temperature for 1 h with 5% FCS in PBS. For immunohistochemistry, 
tissues were incubated with the CD44v6 specific antibody 1.1ASML[18a] 
(5 μg mL−1) in blocking solution over night at 4 °C. After washing three 
times with PBS, sections were incubated with 2nd Alexa488-antibodies 
(Invitrogen) in blocking solution for 2 h at room temperature. Second 
antibodies samples were used as control. For quantum dot stainings, 
the tissues were incubated either with PEG-QDs or 30% v6-PEG-QDs 
(50 μg mL−1 in blocking solution) for 1 h at room temperature. 
Subsequently to the stainings with antibodies or QDs, cells were stained 
with DAPI in PBS for 30 min at room temperature, washed three times 
with PBS, and mounted with fluorescence mounting medium (Dako, 
Glostrup, Denmark). Fluorescence images were taken with a Leica SPE 
laser scanning confocal microscope.
Fluorescence-Activated Cell Sorting (FACS): Expression of CD44v6 
in ASs6 cells was measured by FACS analysis. Cells were seeded at 
a concentration of 5 × 105 cells in 5 cm plates. After 48 h cells were 
detached from the plates using PBS supplemented with 5 × 10−3 m 
ethylendiamine tetraacetate (EDTA) and resuspended in PBS containing 
3% FBS Gold. 1 × 106 cells were incubated with 1.1ASML (1 μg mL−1) 
for 60 min on ice followed by three washing steps. After 30 min of 
incubation with antimouse fluorescein isothiocyanate (FITC)-labeled 
secondary antibody on ice and additional three washing steps the cells 
were resuspended in PBS. The fluorescence was analyzed in a FACScan 
flow cytometer (Becton Dickinson, Heidelberg, Germany).
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